Background and Objectives: Evidence showed that intermittent fasting may
have beneficial effects on metabolic syndrome. However, the results are
controversial and indefinite. This study intends to investigate and assess the
effects of intermittent fasting (IF) on cardiometabolic risk factors in
patients with metabolic syndrome. Methods and Study Design: We searched PubMed, Web of Science, Embase, and Cochrane Library
databases up to July 31, 2022. Primary outcomes included body mass index, fat
mass, fat free mass, body weight, blood pressure, the homeostasis model
assessment of insulin resistance (IR), fasting blood glucose, fasting insulin,
and lipid profiles. Results: Of 4997 retrieved records, 6 met the
inclusion criteria. The meta-analysis showed that IF can significantly reduce BMI (mean difference=-1.56 kg/m2, 95% CI: -2.62
to -0.51), fat mass (mean difference=-1.35%, 95% CI: -2.03 to -0.67), fat free
mass (mean difference=-0.63%, 95% CI: -1.22 to -0.04), body weight (mean
difference=-2.49 kg, 95% CI: -3.11 to -1.88), waist circumference (mean
difference=-3.06 cm, 95% CI: -4.21 to -1.92), and HOMA-IR (mean difference=-0.62,
95% CI: -0.84 to -0.40) compared with non-fasting. However, no statistical
difference was found in the SBP, DBP, TC, TG, LDL-C, HDL-C, fasting blood
glucose, and fasting insulin comparing fasting and non-fasting group. Subgroup
analyses suggested that study duration and sample size may be the source of
heterogeneity for LDL-C. Sensitivity analysis indicated that our results are
reliable and robust. Conclusions: IF could be used for patients with
metabolic syndrome. Further studies with a larger sample size are needed to
verify the effectiveness and safety of IF in patients with metabolic syndrome.